eftilagimod alpha

Sponsor Immutep LTD · listed as IMMP

READOUT Phase 2;Phase 3 Confidence: medium Source: clinicaltrials

eftilagimod alpha is a clinical-stage drug asset sponsored by Immutep LTD, listed as IMMP. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 31, 2026 (day precision, medium confidence), tied to trial NCT05747794. The asset is in Phase 2;Phase 3 and currently active not recruiting, studied in Breast Carcinoma.

Next catalyst

Event typeREADOUT

Expected date2026-10-31

As disclosedOct 31, 2026

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT05747794

PhasePHASE2;PHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorImmutep S.A.S.

Listed asIMMP

Condition(s)Breast Carcinoma

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More IMMP catalysts